抑制NAMPT靶向DNA损伤反应使TP53突变套细胞淋巴瘤对烷化剂化疗增敏
TP53突变套细胞淋巴瘤(MCL)化疗反应差、早期进展,亟需新疗法。NAMPT在MCL细胞系和患者组织中过表达,其抑制剂KPT-9274在TP53突变与野生型MCL细胞中均降低活力并诱导凋亡。机制上,TP53突变细胞中NAMPT抑制通过破坏DNA损伤反应(DDR)通路触发合成致死,而TP53野生型细胞中则选择性抑制B细胞受体(BCR)信号和免疫检查点激活。体内研究证实基于NAMPT的组合在TP53突变异种移植瘤中实现显著肿瘤消退而不加重毒性。
要点
- NAMPT在MCL细胞系和患者组织中过表达,是潜在治疗靶点。
- TP53突变MCL中NAMPT抑制触发DDR通路破坏的合成致死。
- TP53突变细胞对烷化剂和DDR靶向治疗增敏,野生型则可能克服BTK抑制剂耐药。
核心结论
- NAMPT是TP53突变MCL中靶向DNA损伤反应以增敏烷化剂化疗的双情境治疗节点。
研究设计与样本
- 研究使用MCL细胞系和患者组织评估NAMPT表达,并在体外和体内(异种移植瘤)模型测试NAMPT抑制剂KPT-9274单药及联合治疗。
主要发现
- NAMPT抑制剂KPT-9274在TP53突变和野生型MCL细胞中均降低活力并诱导凋亡。
- TP53突变细胞中NAMPT抑制通过破坏DDR通路触发合成致死,并显著增敏烷化剂和DDR靶向治疗。
- TP53野生型细胞中NAMPT抑制选择性抑制BCR信号和免疫检查点激活,并可能克服BTK抑制剂耐药。
- 体内研究显示基于NAMPT的组合在TP53突变异种移植瘤中实现显著肿瘤消退且不加重毒性。
临床怎么用
- 基于TP53状态指导NAMPT抑制剂联合烷化剂或DDR靶向治疗,用于高危TP53突变MCL以克服化疗耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with TP53 mutant mantle cell lymphoma (MCL) face poor chemotherapy response and early progression, requiring novel therapies. Nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting nicotinamide adenine dinucleotide salvage enzyme overexpressed in MCL cell lines and patient tissues, emerges as a therapeutic target. The NAMPT inhibitor KPT-9274 reduced viability and induced apoptosis in MCL cells irrespective of TP53 status. Mechanistic studies reveal a striking dichotomy: in TP53 mutant cells, NAMPT inhibition triggers synthetic lethality through catastrophic DNA damage response (DDR) pathway disruption, whereas in TP53 wild-type cells, it selectively suppresses B-cell receptor (BCR) signaling and immune checkpoint activation. This biological divergence translates to clinically actionable synergies: TP53 mutant cells exhibit marked sensitization to alkylating agents and DDR-targeting therapies, whereas TP53 wild-type models show potential for overcoming BTK inhibitor resistance. In vivo studies confirm that NAMPT-based combinations achieve profound tumor regression in TP53 mutant xenografts without exacerbating toxicity. Our findings establish NAMPT as a dual-context therapeutic node, providing a precision medicine framework to circumvent chemoresistance in high-risk MCL. These results advocate for the clinical evaluation of TP53 status-guided NAMPT inhibitor combinations to address this unmet oncologic challenge.
引用
- Li N, Liu Y, Zhang L, et al. Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. Blood Adv. 2026. PMID: 41428986. doi:10.1182/bloodadvances.2025016765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。